JP2024528982A - Mnk阻害剤による片頭痛の治療方法 - Google Patents

Mnk阻害剤による片頭痛の治療方法 Download PDF

Info

Publication number
JP2024528982A
JP2024528982A JP2024506658A JP2024506658A JP2024528982A JP 2024528982 A JP2024528982 A JP 2024528982A JP 2024506658 A JP2024506658 A JP 2024506658A JP 2024506658 A JP2024506658 A JP 2024506658A JP 2024528982 A JP2024528982 A JP 2024528982A
Authority
JP
Japan
Prior art keywords
alkyl
branched
haloalkyl
hydroxyalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528982A5 (cg-RX-API-DMAC7.html
Inventor
セオドア ジェイ. プライス,
ジェイムズ ジェイ. サーン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2024528982A publication Critical patent/JP2024528982A/ja
Publication of JP2024528982A5 publication Critical patent/JP2024528982A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024506658A 2021-08-05 2022-08-05 Mnk阻害剤による片頭痛の治療方法 Pending JP2024528982A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229882P 2021-08-05 2021-08-05
US63/229,882 2021-08-05
PCT/US2022/039529 WO2023014943A1 (en) 2021-08-05 2022-08-05 Methods of treating migraine with mnk inhibitors

Publications (2)

Publication Number Publication Date
JP2024528982A true JP2024528982A (ja) 2024-08-01
JP2024528982A5 JP2024528982A5 (cg-RX-API-DMAC7.html) 2025-08-13

Family

ID=85154787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506658A Pending JP2024528982A (ja) 2021-08-05 2022-08-05 Mnk阻害剤による片頭痛の治療方法

Country Status (10)

Country Link
US (1) US20250205244A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380566A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024528982A (cg-RX-API-DMAC7.html)
KR (1) KR20240055743A (cg-RX-API-DMAC7.html)
CN (1) CN118076354A (cg-RX-API-DMAC7.html)
AU (1) AU2022324472A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228265A1 (cg-RX-API-DMAC7.html)
IL (1) IL310590A (cg-RX-API-DMAC7.html)
MX (1) MX2024001560A (cg-RX-API-DMAC7.html)
WO (1) WO2023014943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
CN116735759B (zh) * 2023-08-14 2023-11-07 南京威凯尔生物医药科技有限公司 一种高效液相色谱法检测乌布吉泮中间体及其对映体杂质的方法
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors
TW202617153A (zh) * 2024-06-26 2026-05-01 美商4E治療公司 Mnk抑制劑之固態分散體調配物
WO2026006442A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Deuterated mnk inhibitors
WO2026006455A2 (en) * 2024-06-27 2026-01-02 4E Therapeutics, Inc. IMIDAZO [1,5-a] PYRIDINE- 1,5-DIONES AS MNK INHIBITORS AND DEGRADERS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511450A (ja) * 1999-10-08 2003-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング t−ブチル−(7−メチル−イミダゾ[1,2−a]ピリジン−3−イル)−アミン誘導体
JP2006520387A (ja) * 2003-03-14 2006-09-07 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロヒダントインcgrp受容体拮抗物質
JP2017519782A (ja) * 2014-06-25 2017-07-20 イーフェクター セラピューティクス, インコーポレイテッド Mnk阻害薬およびそれに関連する方法
US20190350910A1 (en) * 2017-01-20 2019-11-21 Bayer Pharma Aktiengesellschaft Substituted dihydroimidazopyridinediones as mknk1 and mknk2 inhibitors
WO2020237167A1 (en) * 2019-05-23 2020-11-26 Board Of Regents, The University Of Texas System Inhibitor of mnk for the treatment of neuropathic pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007004618D1 (de) * 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
US10280168B2 (en) * 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
CA3050599A1 (en) * 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511450A (ja) * 1999-10-08 2003-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング t−ブチル−(7−メチル−イミダゾ[1,2−a]ピリジン−3−イル)−アミン誘導体
JP2006520387A (ja) * 2003-03-14 2006-09-07 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロヒダントインcgrp受容体拮抗物質
JP2017519782A (ja) * 2014-06-25 2017-07-20 イーフェクター セラピューティクス, インコーポレイテッド Mnk阻害薬およびそれに関連する方法
US20190350910A1 (en) * 2017-01-20 2019-11-21 Bayer Pharma Aktiengesellschaft Substituted dihydroimidazopyridinediones as mknk1 and mknk2 inhibitors
WO2020237167A1 (en) * 2019-05-23 2020-11-26 Board Of Regents, The University Of Texas System Inhibitor of mnk for the treatment of neuropathic pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR PAIN, vol. Vol.8:6, JPN6026032418, 2012, pages 1 - 9, ISSN: 0005920790 *

Also Published As

Publication number Publication date
AU2022324472A1 (en) 2024-02-15
EP4380566A4 (en) 2025-08-27
CA3228265A1 (en) 2023-02-09
CN118076354A (zh) 2024-05-24
EP4380566A1 (en) 2024-06-12
IL310590A (en) 2024-04-01
MX2024001560A (es) 2024-06-26
US20250205244A1 (en) 2025-06-26
WO2023014943A1 (en) 2023-02-09
KR20240055743A (ko) 2024-04-29

Similar Documents

Publication Publication Date Title
US20250205244A1 (en) Methods of treating migraine with mnk inhibitors
US12110292B2 (en) Ligands to cereblon (CRBN)
JP7796671B2 (ja) Nek7キナーゼの阻害剤
US9314468B2 (en) Chemokine receptor modulators
ES2986581T3 (es) Antagonistas del receptor muscarínico de acetilcolina M4
US20230158157A1 (en) Potent and selective degraders of alk
CA3105748A1 (en) Pyridazine compounds for inhibiting nav1.8
JP2021518389A (ja) IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
US20250066322A1 (en) Substituted heterocyclic compounds
JP2024525480A (ja) Mnk阻害を示すスピロ環式ピリジン-1,5-ジオン及びその使用方法
US20200369650A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20230348437A1 (en) Compounds, compositions and methods
JP2023533616A (ja) Mnk阻害を示すピリジン-1,5-ジオン及びそれらの使用方法
JP2025535057A (ja) フェニルオキシアミドキナーゼ阻害剤
US20260055087A1 (en) Inhibitors of lrrk2 kinase
KR20250005230A (ko) 신경염증성 병태를 치료하는 방법
JP7186874B2 (ja) ピラゾリル化合物およびその使用方法
WO2022226182A1 (en) Nek7 inhibitors
WO2022125614A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
TW202523670A (zh) Pde 7調節劑化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250804

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260731